I agree Eire , the ADAPT platform could have far reaching applications in the future . If the CC gains huge traction ( could very well with the marketing capabilities of Lamitire ) the market will now stand up and take note of any new products Admedus delivers as the ADAPT tech will have proven itself Any future deals / partnerships will command decent compensation not the fire sale price AHZ suffered this time . In the mean time a successful TAVR human implant or two should do wonders for the SP as I suspect it will get a fair amount of media coverage in Australia . This company is learning how to walk again I suggest management they take their time before they try to run like they did previously . Mistakes have been made let’s hope management learnt from them .
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-176
-
- There are more pages in this discussion • 114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.10 |
Change
-0.810(8.17%) |
Mkt cap ! $192.3M | |||
| Open | High | Low | Value | Volume |
| $9.50 | $9.77 | $9.01 | $212.2K | 22.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 298 | $9.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.85 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |